Clinical trials
catalyst calendar across sponsors →Studies where BOLD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 5 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, Qube Research & Technologies Ltd) · FINRA short interest 1.5 days to cover (settled 2026-07-31) · insider 90d: 6 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast CancerNCT07408089Rate of dose limiting toxicities (DLTs) in each BBI-940 monotherapy dose escalation cohort.Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated primarily due to a business decision related to a corporate transaction and was not driven by any safety signal. | Drug: BBI-940, Fulvestrant | Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer | 8 | 2026-07-28actual | 2026-08-19 |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsNCT05827614Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal. | Drug: BBI-355, Erlotinib, Futibatinib, BBI-825 | Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer | 85 | 2026-03-17actual | 2026-08-19 |
| Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene AmplificationsNCT06299761Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-825Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic decision made following an assessment of preliminary PK data from the Part 1 portion of the trial showing a lack of dose proportional exposure and the increasing complexity and associated development costs in this landscape. | Drug: BBI-825 | Solid Tumor | 19 | 2025-06-25actual | 2026-06-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19